One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy

Diabetes Research and Clinical Practice

Volumn 14, Issue 1, 1991, Pages 63-73

  Ziegler, Dan ^a   Mayer, Peter ^a   Rathmann, Wolfgang ^a   Gries, F Arnold ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aldose reductase inhibition; Autonomic function; Diabetic neuropathy; Nerve conduction; Sensory threshold

Indexed keywords

PONALRESTAT;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; COMPARATIVE STUDY; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMAN; MALE; MEDIAN NERVE; MIDDLE AGE; NEUROLOGIC EXAMINATION; PERONEAL NERVE; PHTHALAZINES; REFLEX, PUPILLARY; SUPPORT, NON-U.S. GOV'T; SURAL NERVE; VIBRATION;

EID: 0026075913     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8227(91)90054-H     Document Type: Article

References (47)

1. Understanding diabetic neuropathy
2. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy?
3. Recent advances in the pathogenesis of diabetic neuropathy
4. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
5. Does a common mechanism induce the diverse complications of diabetes?
6. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes
7. The sorbitol pathway and the complications of diabetes
8. +-ATPase regulation involved in pathogenesis of diabetic neuropathy?
9. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat
10. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil
11. Aldose reductase inhibition: studies with alrestatin
12. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy
13. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy
14. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function
15. Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients
16. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus
17. A long-term experimental and clinical study of an aldose reductase inhibitor, ONO-2235, on diabetic neuropathy
18. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy
19. ®) on diabetic neuropathy and neural function of the retina: a double-blind study
20. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy
21. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients
22. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy
23. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial
24. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function
25. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo A double-blind randomized study
26. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment
27. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies on one year's treatment with Sorbinil
28. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy
29. Regeneration and repair of myelinated fibers in suralnerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil
30. A multicentre trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy
31. Biochemical and morphometric response to tolrestat in human diabetic nerve
32. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat
33. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function
34. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy
35. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy
36. Peripheral and autonomic nerve function in long-term insulin-dependent diabetes
37. Graphic representation of pain
38. Assessment of small and large fiber function in long-term type 1 (insulin-dependent) diabetic patients with and without painful neuropathy
39. Microcomputer-based measurement of beat-to-beat intervals and analysis of heart rate variability
40. Clinical experience with sorbinil: an aldose reductase inhibitor
41. Current status of aldose reductase inhibitors
42. Nerve conduction velocity in diabetes
43. Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart-rate variability and vagus nerve structure
44. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats
45. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy
46. Effects of one year of near-normoglycaemia on peripheral nerve function in type 1 (insulin-dependent) diabetic patients
47. The natural course of peripheral and autonomic neural function during the first two years after diagnosis of type 1 diabetes